# Enzo Biochem Inc. (ENZ)

Source: https://www.quantisnow.com/company/ENZ
Generated: 2026-11-02T15:01:56.984Z

- Ticker: ENZ
- Exchange: NYSE
- Sector: Health Care
- Industry: Medical Specialities
- IPO year: 1988
- Website: enzo.com

## About

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 34 patient service centers in New York and New Jersey; and a free-standing ‘STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

## Latest ENZ news and filings

- 2025-06-16 22:40 UTC [Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results](https://www.quantisnow.com/insight/enzo-biochem-reports-third-quarter-fiscal-year-2025-results-6088746)
- 2025-04-22 12:42 UTC [SEC Form 8-K] [Enzo Biochem Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/enzo-biochem-inc-filed-sec-form-8-k-other-events-financial-5995858)
- 2025-04-22 12:30 UTC [Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction](https://www.quantisnow.com/insight/enzo-biochem-inc-announces-review-of-strategic-alternatives-after-receiving-5995809)
- 2025-04-21 13:15 UTC [SEC Form 8-K] [Enzo Biochem Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/enzo-biochem-inc-filed-sec-form-8-k-notice-of-delisting-5994319)
- 2025-04-07 20:15 UTC [SEC Form 25 filed by Enzo Biochem Inc.](https://www.quantisnow.com/insight/sec-form-25-filed-by-enzo-biochem-inc-5979741)
- 2025-03-31 20:22 UTC [SEC Form 8-K] [Enzo Biochem Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/enzo-biochem-inc-filed-sec-form-8-k-notice-of-delisting-5967313)
- 2025-03-28 20:15 UTC [Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX](https://www.quantisnow.com/insight/enzo-biochem-announces-notification-to-new-york-stock-exchange-of-5964871)
- 2025-03-18 20:15 UTC [SEC Form 8-K] [Enzo Biochem Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/enzo-biochem-inc-filed-sec-form-8-k-results-of-operations-5949776)
- 2025-03-17 20:20 UTC [Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results](https://www.quantisnow.com/insight/enzo-biochem-reports-second-quarter-fiscal-year-2025-results-5947432)
- 2025-03-17 20:15 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Enzo Biochem Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-enzo-biochem-inc-5947329)
- 2025-01-17 21:44 UTC [SEC Form 4] [Director Radoff Bradley Louis was granted 142,897 shares, increasing direct ownership by 3% to 4,533,779 units (SEC Form 4)](https://www.quantisnow.com/insight/director-radoff-bradley-louis-was-granted-142897-shares-increasing-direct-5850203)
- 2025-01-17 21:44 UTC [SEC Form 4] [Director Pully Steven J was granted 142,897 shares, increasing direct ownership by 147% to 239,992 units (SEC Form 4)](https://www.quantisnow.com/insight/director-pully-steven-j-was-granted-142897-shares-increasing-direct-5850201)
- 2025-01-17 21:44 UTC [SEC Form 4] [Director Couchman Jonathan was granted 142,897 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-couchman-jonathan-was-granted-142897-shares-sec-form-4-5850200)
- 2025-01-16 21:44 UTC [SEC Form 8-K] [Enzo Biochem Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/enzo-biochem-inc-filed-sec-form-8-k-submission-of-matters-5848698)
- 2025-01-15 21:32 UTC [SEC Form 8-K] [Enzo Biochem Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/enzo-biochem-inc-filed-sec-form-8-k-other-events-5847198)
- 2025-01-14 21:16 UTC [SEC Form 8-K] [Enzo Biochem Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/enzo-biochem-inc-filed-sec-form-8-k-notice-of-delisting-5845602)
- 2025-01-14 21:15 UTC [Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules](https://www.quantisnow.com/insight/enzo-biochem-receives-notice-of-non-compliance-with-new-york-stock-5845561)
- 2024-12-16 21:17 UTC [Dividends] [Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update](https://www.quantisnow.com/insight/enzo-biochem-reports-first-quarter-fiscal-year-2025-results-and-5814940)
- 2024-12-16 21:15 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Enzo Biochem Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-enzo-biochem-inc-5814922)
- 2024-12-02 21:15 UTC [SEC Form 3] [New insider Couchman Jonathan claimed ownership of 447,237 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-couchman-jonathan-claimed-ownership-of-447237-shares-sec-5796050)
- 2024-11-27 21:15 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Enzo Biochem Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-enzo-biochem-inc-5793556)
- 2024-11-25 21:15 UTC [SEC Form 8-K] [Enzo Biochem Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/enzo-biochem-inc-filed-sec-form-8-k-leadership-update-5790258)
- 2024-10-30 00:02 UTC [SEC Form 8-K] [Enzo Biochem Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/enzo-biochem-inc-filed-sec-form-8-k-results-of-operations-5742551)
- 2024-10-29 23:59 UTC [Dividends] [Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend](https://www.quantisnow.com/insight/enzo-biochem-reports-fourth-quarter-and-fiscal-year-2024-results-5742442)
- 2024-10-29 21:04 UTC [SEC Form 10-K] [SEC Form 10-K filed by Enzo Biochem Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-enzo-biochem-inc-5742226)
- 2024-09-24 21:19 UTC [SEC Form 8-K] [Enzo Biochem Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/enzo-biochem-inc-filed-sec-form-8-k-other-events-5703801)
- 2024-08-14 20:15 UTC [SEC Form 8-K] [Enzo Biochem Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/enzo-biochem-inc-filed-sec-form-8-k-other-events-5659299)
- 2024-08-02 20:15 UTC [SEC Form 8-K] [Enzo Biochem Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/enzo-biochem-inc-filed-sec-form-8-k-leadership-update-5640351)
- 2024-07-25 21:23 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Eckert Patricia](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-eckert-patricia-5628932)
- 2024-07-25 21:22 UTC [SEC Form 8-K] [Enzo Biochem Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/enzo-biochem-inc-filed-sec-form-8-k-leadership-update-financial-5628929)
- 2024-07-24 23:50 UTC [SEC Form 4] [Chief Executive Officer Cannon Kara covered exercise/tax liability with 70,885 shares, decreasing direct ownership by 16% to 380,412 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-cannon-kara-covered-exercisetax-liability-with-70885-5626275)
- 2024-06-26 21:13 UTC [SEC Form 11-K] [SEC Form 11-K filed by Enzo Biochem Inc.](https://www.quantisnow.com/insight/sec-form-11-k-filed-by-enzo-biochem-inc-5579359)
- 2024-06-13 20:23 UTC [Market Chatter] [Enzo Biochem Q3 EPS $(0.06), Sales $8.00M](https://www.quantisnow.com/insight/enzo-biochem-q3-eps-006-sales-800m-5556602)
- 2024-06-13 20:20 UTC [Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update](https://www.quantisnow.com/insight/enzo-biochem-reports-third-quarter-fiscal-2024-results-and-provides-5556548)
- 2024-06-13 20:15 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Enzo Biochem Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-enzo-biochem-inc-5556493)
- 2024-05-24 20:46 UTC [SEC Form 4] [SEC Form 4 filed by Cannon Kara](https://www.quantisnow.com/insight/sec-form-4-filed-by-cannon-kara-5517288)
- 2024-05-24 20:44 UTC [SEC Form 8-K] [Enzo Biochem Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/enzo-biochem-inc-filed-sec-form-8-k-leadership-update-financial-5517259)
- 2024-04-10 12:12 UTC [Market Insight] [Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket](https://www.quantisnow.com/insight/why-pricesmart-shares-are-trading-higher-by-around-5-here-5402152)
- 2024-03-13 20:31 UTC [SEC Form 8-K] [Enzo Biochem Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/enzo-biochem-inc-filed-sec-form-8-k-results-of-operations-5341802)
- 2024-03-13 20:31 UTC [Market Insight] [Enzo Biochem Q2 EPS $(0.06) Up From $(0.23) YoY, Sales $8.55M](https://www.quantisnow.com/insight/enzo-biochem-q2-eps-006-up-from-023-yoy-sales-5341757)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ENZ
- Earnings history: https://www.quantisnow.com/earnings/ENZ
- Dividend history: https://www.quantisnow.com/dividends/ENZ
- Insider transactions: https://www.quantisnow.com/insiders/ENZ
- Options chain: https://www.quantisnow.com/options/ENZ
- SEC 8-K filings only: https://www.quantisnow.com/company/ENZ/8-k
- RSS and alerts for ENZ: https://www.quantisnow.com/docs/rss-feeds.md